BR112017004810A2 - imunoensaio - Google Patents

imunoensaio

Info

Publication number
BR112017004810A2
BR112017004810A2 BR112017004810A BR112017004810A BR112017004810A2 BR 112017004810 A2 BR112017004810 A2 BR 112017004810A2 BR 112017004810 A BR112017004810 A BR 112017004810A BR 112017004810 A BR112017004810 A BR 112017004810A BR 112017004810 A2 BR112017004810 A2 BR 112017004810A2
Authority
BR
Brazil
Prior art keywords
human
drug
sample
receptor
binding fragment
Prior art date
Application number
BR112017004810A
Other languages
English (en)
Inventor
Stubenrauch Kay-Gunnar
Umaña Pablo
Wessels Uwe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112017004810A2 publication Critical patent/BR112017004810A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

no presente pedido é relatado um imunoensaio de anticorpo anti-droga para a determinação da presença de um anticorpo anti-droga contra um anticorpo droga humano ou humanizado com função efetora suprimida em uma amostra, que compreende a incubação de uma amostra que compreende soro de sangue de mamífero com receptor fcgama i humano inteiro ou um fragmento de ligação de região fc do mesmo, de modo que um complexo entre o anticorpo anti-droga contra o anticorpo droga humano ou humanizado com função efetora suprimida presente na amostra e o receptor fcgama i humano ou o fragmento de ligação de região fc do mesmo se forme, através da qual o receptor fcgama i humano inteiro ou o fragmento de ligação de região fc do mesmo é conjugado a um marcador detectável, e a determinação do complexo formado pelo marcador detectável.
BR112017004810A 2014-11-05 2015-10-22 imunoensaio BR112017004810A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14191806 2014-11-05
PCT/EP2015/074495 WO2016071119A1 (en) 2014-11-05 2015-10-22 Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody

Publications (1)

Publication Number Publication Date
BR112017004810A2 true BR112017004810A2 (pt) 2017-12-12

Family

ID=52023155

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004810A BR112017004810A2 (pt) 2014-11-05 2015-10-22 imunoensaio

Country Status (10)

Country Link
US (1) US11340234B2 (pt)
EP (2) EP3215853B1 (pt)
JP (2) JP6739428B2 (pt)
KR (1) KR20170080590A (pt)
CN (1) CN107076761B (pt)
BR (1) BR112017004810A2 (pt)
CA (1) CA2960453A1 (pt)
MX (1) MX2017005156A (pt)
RU (1) RU2719642C2 (pt)
WO (1) WO2016071119A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090061466A1 (en) * 2006-03-09 2009-03-05 Wolfgang Hoesel Anti-drug antibody assay
US20210231654A1 (en) * 2018-06-04 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Method for detecting complex
US11448651B2 (en) * 2018-07-10 2022-09-20 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-exisiting interactions
WO2024165456A1 (en) * 2023-02-07 2024-08-15 F. Hoffmann-La Roche Ag Method for the detection of anti-aav particle antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219730A (en) 1982-09-28 1993-06-15 New York University Idiotype-anti-idiotype immunoassay
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
EP0170302A1 (fr) 1984-06-27 1986-02-05 l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques
EP0243471A4 (en) 1985-10-22 1989-07-11 Cooper Lipotech Inc SOLID PHASE LIPOSOME IMMUNOANALYSIS SYSTEM.
WO1994001451A2 (en) 1992-07-13 1994-01-20 Bionebraska, Inc. Method for modification of recombinant polypeptides
US6753189B1 (en) 1998-06-04 2004-06-22 Mizuho Medy Co., Ltd. Detection apparatus and method for the same
EP1917854A1 (en) 2006-11-06 2008-05-07 F. Hoffmann-La Roche Ag Method for producing anti idiotypic antibodies
WO2009077127A1 (en) * 2007-12-15 2009-06-25 F. Hoffmann-La Roche Ag Distinguishing assay
AU2009246516B2 (en) * 2008-05-13 2015-03-05 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
JP5560198B2 (ja) 2008-11-05 2014-07-23 帝人株式会社 ポリ乳酸組成物の製造方法
EP2496601B1 (en) * 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methods and composition for secretion of heterologous polypeptides
EP2354792A1 (en) * 2010-02-08 2011-08-10 Biomonitor A/S Method for detecting anti-drug antibodies
SI2564202T1 (sl) * 2010-04-29 2015-12-31 Theradiag Sa Metode za odkrivanje protiteles proti zdravilu
DK2676137T3 (en) * 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
EP2492689B8 (en) * 2011-02-22 2013-12-25 Bernhard-Nocht-Institut für Tropenmedizin Detection of antibodies using an improved immune complex (IC) ELISA
MY163539A (en) * 2011-03-29 2017-09-15 Roche Glycart Ag Antibody fc variants
CN107903325B (zh) * 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof

Also Published As

Publication number Publication date
JP6739428B2 (ja) 2020-08-12
US20170343560A1 (en) 2017-11-30
EP3736575C0 (en) 2024-08-28
MX2017005156A (es) 2017-08-08
CN107076761B (zh) 2020-05-05
US11340234B2 (en) 2022-05-24
EP3736575A1 (en) 2020-11-11
EP3736575B1 (en) 2024-08-28
CA2960453A1 (en) 2016-05-12
KR20170080590A (ko) 2017-07-10
JP2017532570A (ja) 2017-11-02
RU2719642C2 (ru) 2020-04-21
EP3215853A1 (en) 2017-09-13
EP3215853B1 (en) 2022-11-16
WO2016071119A1 (en) 2016-05-12
RU2017117273A3 (pt) 2019-05-14
JP2020170001A (ja) 2020-10-15
CN107076761A (zh) 2017-08-18
RU2017117273A (ru) 2018-12-06

Similar Documents

Publication Publication Date Title
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
BR112019000872A2 (pt) métodos para quantificar anticorpos individuais de uma mistura
BR112017004899A2 (pt) detecção de proteínas mal dobradas
BR112017004810A2 (pt) imunoensaio
MX2020004921A (es) Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo.
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
BR112016007112A2 (pt) Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
BR112018016337A2 (pt) anticorpos monoclonais da proteína ns1 de vírus antidengue
BR112017004773A2 (pt) biomarcadores para avaliar câncer de mama
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BR112015023262B8 (pt) Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112016002685A2 (pt) ensaios para timp2 que apresentam melhor desempenho em amostras biológicas
BR112016010106A2 (pt) ensaios para igfbp7 com melhor desempenho em amostras biológicas
BR112015022844A2 (pt) métodos para detecção de anticorpos para doadores específicos e sistemas para pratica destes
BR112018005812A2 (pt) ?método de imunoensaio para a detecção de um analito, kit de reagentes para detectar um analito por um imunoensaio e uso de um parceiro de ligação marcador-específico?
BR112015015086A2 (pt) calibração de válvula de fluido acústico
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
BR112019008279A2 (pt) uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
BR112022001693A2 (pt) Construtos de proteína de ligação ao antígeno e usos dos mesmos
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
BR112018007842A2 (pt) imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk)

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2693 DE 16-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.